8.985

0.39% 0.025

Biocryst Pharmaceuticals Inc (BCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BCRX? Forum Prognose

Schlusskurs vom Vortag:

$8.96

Offen:

$8.98

24-Stunden-Volumen:

455.21K

Relative Volume:

0.11

Marktkapitalisierung:

$2.30B

Einnahmen:

$503.49M

Nettoeinkommen (Verlust:

$-53.47M

KGV:

-34.56

EPS:

-0.26

Netto-Cashflow:

$-26.89M

1W Leistung:

-9.42%

1M Leistung:

-16.33%

6M Leistung:

+19.61%

1J Leistung:

+34.86%

1-Tages-Spanne:

$8.91

$9.06

1-Wochen-Bereich:

$8.91

$10.07

52-Wochen-Spanne:

$6.015

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Firmenname

Biocryst Pharmaceuticals Inc

Sektor

Healthcare (1174)

Branche

Drug Manufacturers - Specialty & Generic (84)

Telefon

919-859-1302

Adresse

4505 EMPEROR BOULEVARD, DURHAM, NC

Mitarbeiter

580

Twitter

@biocrystpharma

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

BCRX's Discussions on Twitter

Vergleichen Sie BCRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCRX Biocryst Pharmaceuticals Inc	9.00	2.30B	503.49M	-53.47M	-26.89M	-0.26
RGC Regencell Bioscience Holdings Ltd	16.40	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	155.82	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.34	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.43	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.64	20.17B	16.54B	-1.64B	749.00M	-1.45

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2025-02-25	Eingeleitet	Wedbush	Outperform
2023-11-20	Fortgesetzt	JP Morgan	Overweight
2023-09-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Hochstufung	Jefferies	Hold → Buy
2023-07-13	Hochstufung	BofA Securities	Neutral → Buy
2023-02-22	Hochstufung	Needham	Hold → Buy
2022-11-02	Hochstufung	Evercore ISI	In-line → Outperform
2022-08-05	Herabstufung	Evercore ISI	Outperform → In-line
2022-08-05	Herabstufung	Oppenheimer	Outperform → Perform
2022-04-18	Herabstufung	Barclays	Overweight → Equal Weight
2022-04-11	Herabstufung	BofA Securities	Buy → Neutral
2021-12-10	Eingeleitet	Oppenheimer	Outperform
2021-08-06	Herabstufung	Jefferies	Buy → Hold
2021-08-03	Eingeleitet	Cantor Fitzgerald	Overweight
2021-03-01	Eingeleitet	Cowen	Outperform
2020-09-29	Fortgesetzt	JP Morgan	Overweight
2020-06-17	Eingeleitet	BTIG Research	Neutral
2020-05-05	Hochstufung	Barclays	Equal Weight → Overweight
2019-11-15	Hochstufung	BofA/Merrill	Neutral → Buy
2019-05-24	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Fortgesetzt	Piper Jaffray	Overweight
2018-08-08	Fortgesetzt	JP Morgan	Overweight
2018-07-17	Hochstufung	BofA/Merrill	Underperform → Neutral
2018-06-22	Eingeleitet	Seaport Global Securities	Neutral
2018-01-02	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Eingeleitet	Barclays	Equal Weight
2017-09-15	Eingeleitet	RBC Capital Mkts	Sector Perform
2017-09-06	Hochstufung	JP Morgan	Neutral → Overweight
2017-09-06	Hochstufung	Jefferies	Hold → Buy
2017-02-16	Eingeleitet	Ladenburg Thalmann	Buy
2016-08-12	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-08-04	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	FBR Capital	Outperform
2016-02-09	Herabstufung	JP Morgan	Overweight → Neutral
2016-02-09	Herabstufung	Needham	Buy → Hold

Alle ansehen

Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten

Jun 18, 2025

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Nasdaq

Jun 18, 2025

Jun 16, 2025

BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks

Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa

Jun 16, 2025

Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News

Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia

Jun 16, 2025

BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus

Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus

Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire

Jun 16, 2025

ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan

Jun 16, 2025

Jun 13, 2025

Sector Update: Health Care Stocks Lean Lower Premarket Friday - MarketScreener

Jun 13, 2025

BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com

Jun 13, 2025

Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada

Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus

Jun 13, 2025

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com

Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus

Jun 13, 2025